Etaracizumab (LM 609) is an alphavbeta3 integrin IgG mAb. Etaracizumab is developed to target alphavbeta3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofalphavbeta3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001)[1][2][3][4][5].
Molecular Weight:
(146.64 kDa)
Purity:
99.81
CAS Number:
[892553-42-3]
Target:
Akt,Apoptosis,Integrin
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
